Description: Stability and Storage:The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. Detection method:Colorimetric Sample type:Plasma, Serum Assay type:Quantitative Sensitivity:0.156 μg/ml Range:0.31-5 μg/mL Recovery:80-120% Background:Vanucizumab (RG7221) is an experimental humanized monoclonal antibody (mAb) designed for the treatment of cancer. Vanucizumab is a bi-specific mAb composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding vascular endothelial growth factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech/Roche. On 12 Mar 2018, Roche completes a phase I trial in solid tumors (combination therapy, late-stage disease, metastatic disease, second-line therapy or greater) in Spain, France, and Belgium. Shipping:2-8 ℃ Specifications:Vanucizumab Note:For Research Use Only.